



Cancer Research UK China Fellows Programme 2009

Projects by cancer types

Acute Myeloid Leukaemia

Cardiff

Identification of therapeutic targets in acute myeloid leukaemia using kinomics

Professor Alan Burnett, Dr Richard Darley, Dr Alex Tonks and Dr Steve Knapper

Departments of Haematology and Surgery, Cardiff University

Bladder Cancer

Birmingham

The South and East China case control study on prostate and bladder cancer

Professor Maurice Zeegers and Professor K K Cheng

Department of Public Health and Epidemiology, University of Birmingham

Leeds

Role of DNA damage signalling in bladder cancer

Dr Anne Kiltie and Professor Tim Bishop

Cancer Research UK Clinical Centre, University of Leeds

Autocrine and paracrine signalling via FGF receptors in bladder cancer

Professor Margaret Knowles

Cancer Research UK Clinical Centre, University of Leeds

Leicester

A novel approach to treating metastatic bladder cancer: targeting the function of the transcription factor, ZEB1

Dr Eugene Tulchinsky, Dr Marina Kriajevska and Dr Maxim G. Ryadnov

University of Leicester

Breast Cancer

Belfast

The role of Tcf-4/ β -catenin in osteopontin regulation of human breast cancer

Dr Mohamed El-Tanani and Professor Patrick Johnston
Cancer Research Centre, Queen's University of Belfast

Leicester

Multi-gene analysis in plasma and tumour of breast cancer patients for prediction of overt metastases and resistance to therapy

Dr Jacqueline Amanda Shaw
University of Leicester

London

Control of drug resistance in breast cancer cells by micro RNAs

Dr Ernesto Yagüe and Professor Charles Coombes
Department of Medical Oncology, Imperial College London

Role of PI3K/FOXO/FOXM signalling axis in mediating sensitivity and resistance to endocrine and chemotherapy in breast cancer

Professor Eric W-F Lam
Department of Medical Oncology, Imperial College London

Utilising next generation sequencing approaches to study drug resistance and tumour evolution

Professor Alan Ashworth
The Institute of Cancer Research

Oxford

To understand the mechanisms of response and resistance to Herceptin (Trastuzumab) and other targeted therapies in breast cancer

Dr Anthony Kong and Professor Adrian Harris
Weatherall Institute of Molecular Medicine, University of Oxford

Colorectal Cancer

Leicester

Development of methoxylated flavones as colorectal cancer chemopreventive agents

Professor William Steward and Dr Stewart Sale
University of Leicester

Head and Neck Squamous Cell Carcinoma

Liverpool

Using fluorochrome-tagged ligands of EGFR and VEGFR to examine and treat squamous cell carcinoma of the head and neck *in vivo*

Dr Mark T. Boyd, Dr Terence M. Jones, Dr Joseph Backer and Professor John Neoptolemos
University of Liverpool

Preclinical development and evaluation of (+)-Leucascandrolide A

Dr P. Andrew Evans and Professor B. Kevin Park
University of Liverpool

Kaposi's Sarcoma

Birmingham

Understanding modulation of the type I interferon response by the Kaposi's sarcoma-associated herpesvirus vIRF2 protein

Dr David J. Blackbourn and Professor Paul Moss
Cancer Research UK Institute for Cancer Studies, University of Birmingham

Lung Cancer

Belfast

Prognostic significance and proapoptotic targeting of BAX and BAK immunonegative non-small cell lung cancer

Dr Dean A. Fennell
Cancer Research Centre, Queen's University of Belfast

Edinburgh

Identification protein factors involved in the epigenetic inactivation of tumour suppressor gene TCF21

Dr Irina Stancheva

Institute of Cell Biology, University of Edinburgh

London

Role of ADCK family members in non-small cell lung cancer cell motility and invasion

Professor Michael J. Seckl and Dr Olivier E. Pardo

Department of Medical Oncology, Imperial College London

Oxford

Smoking, indoor air pollution, nutrition, chronic infection and risks of lung cancer and COPD in a cohort study of 0.5M adults

Professor Zhengming Chen

Clinical Trial Service Unit & Epidemiological Studies Unit, University of Oxford

Melanoma

Birmingham

Can optimal co-stimulation enhance the ability of T cells from melanoma patients to respond to tumour antigens?

Dr Peter Searle, Dr Jane Steele and Professor Paul Moss

Cancer Research UK Institute for Cancer Studies, University of Birmingham

Liverpool

Analysis of genomic characteristics in primary and metastatic uveal melanomas, with examination of serum marker dynamics

Dr Sarah E. Coupland, Professor Bertil Damato, Dr H Kalirai and Professor John Neoptolemos

University of Liverpool

Manchester

Rac in malignant progression of melanoma

Dr Adam Hurlstone and Dr Stephen Taylor

Faculty of Life Sciences, University of Manchester

Nasopharyngeal Cancer

Birmingham

The contribution of EBV-induced aberrant lipid signalling to the pathogenesis of nasopharyngeal cancer

Professor Paul Murray, Dr Chris Dawson, Professor Ciaran Woodman, Professor Lawrence Young

Cancer Research UK Institute for Cancer Studies, University of Birmingham

Ovarian Cancer

London

The transcriptional regulation of specific miRNAs and their targets in ovarian and chemo-resistant cancers

Professor Hani Gabra and Dr Justin Stebbing

Department of Medical Oncology, Imperial College London

Utilising next generation sequencing approaches to study drug resistance and tumour evolution

Professor Alan Ashworth

The Institute of Cancer Research

Characterisation of the functionality of dendritic cells in ovarian tumour patients

Dr Sandra Diebold

Immunobiology Department, King's College London

Pancreatic Cancer

Edinburgh

Modulating drug resistance in pancreatic cancer

Professor Margaret Frame

Cancer Research Centre, University of Edinburgh

Liverpool

Identification of cancer biomarkers and development of multiple reactions monitoring for biomarker quantification and validation

Dr Eithne Costello and Professor John Neoptolemos

University of Liverpool

Prostate Cancer

Birmingham

The South and East China case control study on prostate and bladder cancer

Professor Maurice Zeegers and Professor K K Cheng

Department of Public Health and Epidemiology, University of Birmingham

Cardiff

Molecular and cellular dissection of the role of prostate transglutaminase (TGase-4) in regulating the behaviour of cancer cells

Professor Alan Burnett and Professor Wen G Jiang

Departments of Haematology and Surgery, Cardiff University

London

Molecular inhibition of androgen signalling in prostate cancer

Dr Charlotte Bevan and Dr Greg Brooke

Department of Medical Oncology, Imperial College London

Retinoblastoma

London

Structural basis of retinoblastoma tumour suppressor protein regulation and functioning

Professor Sibylle Mitnacht, Dr Edward Morris and Professor Laurence Pearl

The Institute of Cancer Research

All Cancer Types

Birmingham

Development of an intervention to prevent childhood obesity in China

Dr Peymané Adab and Professor K K Cheng

Department of Public Health and Epidemiology, University of Birmingham

Establishing smoking cessation services in China: evidence base, design and evaluation

Professor K K Cheng

Department of Public Health and Epidemiology, University of Birmingham

Gene and environmental determinants of common cancers in south China

Dr G Neil Thomas and Professor K K Cheng

Department of Public Health and Epidemiology, University of Birmingham

Structural basis of claudin interactions which define epithelial cell polarity and mediate hepatitis C virus internalization

Professor Michael Overduin and Professor Jane McKeating

Cancer Research UK Institute for Cancer Studies, University of Birmingham

Structural biology of signalling and immune evasion mediated by the sole GPCR encoded by the Epstein Barr virus

Professor Martin Rowe, Professor Michael Overduin and Dr Roslyn M Bill

Cancer Research UK Institute for Cancer Studies, University of Birmingham

Cambridge

Nanometer scale dissection of the architecture and dynamics of irradiation induced foci

Dr Catherine Green

Department of Zoology, University of Cambridge

Dundee

The dynamics of replication licensing in normal and cancer cells

Professor John Julian Blow

University of Dundee

Regulation of apoptosis during mitosis and in response to anti-mitotic drugs

Professor Paul R. Clarke and Professor C. Roland Wolf

University of Dundee

Mechanism of chromosome acrobatics: how is the kinetochore-microtubule interface regulated in mitosis?

Dr Tomoyuki Tanaka

University of Dundee

Edinburgh

Identification of apoptotic signalling pathways used by direct acting GnRH analogues in GnRH receptor expressing cancers

Professor David Harrison, Dr Simon Langdon, Dr Kevin Morgan and Professor Robert Millar

Cancer Research Centre, University of Edinburgh

Glasgow

Analysis of signalling regulators of the p53-mediated autophagic response

Professor Kevin Ryan

The Beatson Institute for Cancer Research

Liverpool

De-ubiquitination and the regulation of cancer associated signalling pathways

Dr Sylvie Urbé and Professor Michael Clague

University of Liverpool

London

The mechanism of protein kinase activation by the HSP90 molecular chaperone system

Professor Laurence H. Pearl

The Institute of Cancer Research

Integration of the use of circulating biomarkers of response and molecular characterization of tumours to improve patient care

Dr Udai Banerji and Professor Stan Kaye

The Institute of Cancer Research

Genetic modification of T cells to function in tolerogenic tumour environment

Dr Jian-Guo Chai

Department of Immunology, Hammersmith Hospital, Imperial College London

A combined intravital fluorescence lifetime imaging/mass spectrometry approach to understand the CXCR4 signalosome in cancers

Professor Tony Ng, Professor Qingbo Xu and Dr Lingfang Zeng

Division of Cancer Studies & Randall Division of Cell & Molecular Biophysics, King's College London

Synthesis and chemical biology of novel telomeric quadruplex targeting agents

Professor Stephen Neidle

The School of Pharmacy, University of London

Use and development of novel analytical methodologies and chemical probes to investigate tertiary DNA structures

Professor David Thurston

The School of Pharmacy, University of London

Functionalisation and proteomics analysis of cancer chemopreventive agents for molecular target identification

Dr Geoff Wells

The School of Pharmacy, University of London

Manchester

Poly(ADP-ribosyl)ation in regulation of DNA damage response

Dr Ivan Ahel

Paterson Institute for Cancer Research

Comprehensive, integrated, proteomic and transcriptomic analysis of cell cycle control

Professor Iain Hagan and Dr Crispin Miller

Paterson Institute for Cancer Research

Investigation of mechanisms limiting tumour-specific immune responses and strategies for improving anti-tumour immune responses

Professor Robert E. Hawkins, Dr Eyad Elkord and Dr Dominic Rothwell

Department of Medical Oncology, University of Manchester

The impact of targeted therapies upon the tumour immune microenvironment

Professor Robert E. Hawkins, Dr David Gilham and Dr Paul Lorigan

Department of Medical Oncology, University of Manchester

Oxford

DNA damage dependent ARF signalling and cancer

Dr Grigory Dianov

Gray Institute for Radiation Oncology & Biology

Selective cytotoxic treatment for mismatch repair defective tumours using a synthetic lethal approach

Professor Thomas Helleday

Gray Institute for Radiation Oncology & Biology

Molecular mechanisms of nuclear accumulation of anticancer radiopharmaceuticals

Dr Katherine A. Vallis

Gray Institute for Radiation Oncology & Biology

Sheffield

JAK/STAT pathway signalling and the regulation of heterochromatin

Dr Martin Zeidler

Department of Biomedical Science, University of Sheffield